<DOC>
	<DOCNO>NCT00336986</DOCNO>
	<brief_summary>This trial conduct Oceania . A phase 2a study assess effect tumor size . At least 14 maximum 40 patient , previously receive treatment stage IV disease , treat 6 week . IL-21 administer intravenously .</brief_summary>
	<brief_title>Efficacy Study IL-21 Treat Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm surgically incurable metastatic melanoma Patients must measurable disease ECOG performance status 0 1 Expected life expectancy least 4 month History signs/symptoms uncontrolled brain metastasis edema . Previous treatment chemotherapy biological anticancer drug ( prior adjuvant therapy interferonalpha permit long treatment complete least six month prior study entry . ) Radiotherapy : Radiation therapy within 4 week prior enter study . Receipt investigational drug treatment metastatic melanoma prior trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>